Association between dupilumab and rituximab in a patient with severe atopic dermatitis and minimal change disease

Ital J Dermatol Venerol. 2022 Jun;157(3):283-284. doi: 10.23736/S2784-8671.21.07016-X. Epub 2021 May 28.

Authors

Maurizio Romagnuolo¹, Davide Riva², Simona Tavecchio^{2

3}, Emilio F Berti^{2

3}, Silvia M Ferrucci³

Affiliations

¹ Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy - maurizio.romagnuolo@unimi.it.
² Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.
³ Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

PMID: 34044513
DOI: 10.23736/S2784-8671.21.07016-X

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects
Dermatitis, Atopic* / drug therapy
Humans
Nephrosis, Lipoid*
Rituximab / adverse effects

Substances

Antibodies, Monoclonal, Humanized
dupilumab
Rituximab